Skip to main content

Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

Publication ,  Journal Article
Bateman, NW; Abulez, T; Soltis, AR; McPherson, A; Choi, S; Garsed, DW; Pandey, A; Tian, C; Hood, BL; Conrads, KA; Teng, PN; Oliver, J; Yan, C ...
Published in: Npj Precision Oncology
December 1, 2024

We performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade serous ovarian cancer (HGSOC) tissue specimens spanning a broad spectrum of purity. We identified patients with longer progression-free survival had increased immune-related signatures and validated proteins correlating with tumor-infiltrating lymphocytes in 65 tumors from an independent cohort of HGSOC patients, as well as with overall survival in an additional 126 HGSOC patient cohort. We identified that homologous recombination deficient (HRD) tumors are enriched in pathways associated with metabolism and oxidative phosphorylation that we validated in independent patient cohorts. We further identified that polycomb complex protein BMI-1 is elevated in HR proficient (HRP) tumors, that elevated BMI-1 correlates with poor overall survival in HRP but not HRD HGSOC patients, and that HRP HGSOC cells are uniquely sensitive to BMI-1 inhibition.

Duke Scholars

Published In

Npj Precision Oncology

DOI

EISSN

2397-768X

Publication Date

December 1, 2024

Volume

8

Issue

1

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bateman, N. W., Abulez, T., Soltis, A. R., McPherson, A., Choi, S., Garsed, D. W., … Goode, E. L. (2024). Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. Npj Precision Oncology, 8(1). https://doi.org/10.1038/s41698-024-00519-8
Bateman, N. W., T. Abulez, A. R. Soltis, A. McPherson, S. Choi, D. W. Garsed, A. Pandey, et al. “Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.” Npj Precision Oncology 8, no. 1 (December 1, 2024). https://doi.org/10.1038/s41698-024-00519-8.
Bateman NW, Abulez T, Soltis AR, McPherson A, Choi S, Garsed DW, et al. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. Npj Precision Oncology. 2024 Dec 1;8(1).
Bateman, N. W., et al. “Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.” Npj Precision Oncology, vol. 8, no. 1, Dec. 2024. Scopus, doi:10.1038/s41698-024-00519-8.
Bateman NW, Abulez T, Soltis AR, McPherson A, Choi S, Garsed DW, Pandey A, Tian C, Hood BL, Conrads KA, Teng PN, Oliver J, Gist G, Mitchell D, Litzi TJ, Tarney CM, Crothers BA, Mhawech-Fauceglia P, Dalgard CL, Wilkerson MD, Pierobon M, Petricoin EF, Yan C, Meerzaman D, Bodelon C, Wentzensen N, Lee JSH, Huntsman DG, Shah S, Shriver CD, Phippen NT, Darcy KM, Bowtell DDL, Conrads TP, Maxwell GL, Makohon-Moore SC, Barakat W, Zhang X, Hunt A, Ao W, Lytle-Gabbin SL, Casablanca Y, Hamilton CA, Newell M, Wells J, Sukumar G, Bacikova D, Freyman J, Cohn DE, Berchuck A, Havrilesky L, Duska L, Odunsi A, Sood A, Brenton J, Sala E, Annunziata C, Dorigo O, Nelson B, Cochrane DR, Moore K, Baldelli E, Chen QR, Hu Y, Fereday S, Traficante N, DeFazio A, Goode EL. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. Npj Precision Oncology. 2024 Dec 1;8(1).

Published In

Npj Precision Oncology

DOI

EISSN

2397-768X

Publication Date

December 1, 2024

Volume

8

Issue

1

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology